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Abstract
Objective—To compare patient retention at three stages of pre-antiretroviral (ART) care and two
stages of post-ART care to identify when greatest attrition occurs.
Design—An observational cohort study.
Methods—We reviewed files of all adult, non-pregnant individuals testing HIV-positive January
1 – June 30, 2010, at a primary health clinic in Johannesburg, South Africa (N=842). We
classified retention in pre-ART stage 1 (HIV diagnosis to CD4 results notification in ≤3 months),
pre-ART stage 2 (initially ineligible for ART with repeat CD4 test ≤1 year of prior CD4), pre-
ART stage 3 (initiating ART ≤3 months after first eligible CD4 result), as well as at 0–6 and 6–12
months post-ART.
Results—Retention among all patients during pre-ART stage 1 was 69.8% (95%CI 66.7–72.9%).
For patients initially ART-ineligible (n=221), 57.4% (95%CI 49.5–65.0%) returned for a repeat
CD4 during pre-ART stage 2. Among those ART-eligible (n=589), 73.5% (95%CI 69.0–77.6%)
were retained during pre-ART stage 3. Retention increased with time on ART, from 80.2%
(95%CI 75.3–84.5%) at 6 months to 95.3% (95%CI 91.7–97.6%) between 6–12 months.
Cumulative retention from diagnosis to 12 months on ART was 36.9% (95%CI 33.0–41.1%) for
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those ART-eligible and 43.0% (95%CI 36.4–49.8%) from diagnosis to repeat CD4 testing within
one year among those ART-ineligible.
Conclusions—Patient attrition in the first year following HIV diagnosis was greatest prior to
ART initiation: over 25% at each of three pre-ART stages. As countries expand HIV testing and
ART programs, success will depend on linkage to care, especially prior to ART eligibility and
initiation.
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Introduction
South Africa’s national antiretroviral therapy (ART) program is currently the largest in the
world, with over 1.7 million adults and children enrolled in the first seven years.1,2 Rapid
scale-up has put tremendous pressure on the limited resources of the public health sector.
Despite the fact that 300,000 patients enroll in the South African ART program each year,3
an estimated 250,000 people died of AIDS in 20104 and only 52% of those currently ART-
eligible are receiving treatment.2
An enormous challenge to South Africa’s attempts to expand the impact of its program is
attrition from HIV care. Uninterrupted retention for HIV patients is critical as patients who
stop treatment are at increased risk of drug resistance, morbidity and mortality.5,6 Several
studies have documented rates of retention on ART in resource-limited settings,7–11 and
have demonstrated that during the first year on HIV treatment patients are at high risk for
attrition (i.e., programmatic loss and mortality).9,12,13 More recent work has documented
high rates of attrition among patients not yet on ART from the time of testing positive to
completion of CD4 staging,14,15 from completing staging to repeat CD4 testing for ART
eligibility,16,17 and from ART eligibility to ART initiation.16,18,19
While these studies highlight a problem with attrition from HIV care, three major limitations
impede conclusions about the extent of the problem. First, progression through the
consecutive stages of HIV care (e.g., testing positive, CD4 staging, ART initiation) are
typically studied in isolation among distinct cohorts which prevents a measure of overall
program attrition from the time of testing positive through long-term ART. To our
knowledge, only one study has examined retention through pre-ART and post-ART stages
among patients in Southern Africa. Using data from the first year of the public ART
program (2004–2005) in Mozambique, Micek et al. reported data from separate HIV testing
and treatment facilities and found retention was lowest at the period of enrollment at the
ART sites (56.5%) and for timely ART initiation among ART-eligible (31.3%), but did not
report cumulative retention through all stages or describe retention among patients ineligible
for ART.20 Second, operational definitions of patient retention differ greatly between
studies, limiting comparability. Recommendations for standardized definitions for pre-ART
care have recently been proposed,21 allowing for estimates that can be compared across
programs and countries. Third, most national HIV programs do not report retention indictors
during pre-ART care, so we currently have no way of quantifying the magnitude of loss to
initiation at the country level.
To address the limited longitudinal measures of attrition from HIV care across multiple
stages of care, we set out to measure attrition through five stages of early HIV care at a
single site in a cohort of patients testing positive using the newly recommended definitions.
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Witkoppen Health and Welfare Centre (“Witkoppen”) is a high-volume (8,500 patient visits
per month) primary healthcare clinic in Johannesburg, South Africa, operated by a non-
governmental organization receiving public and private financial support. Witkoppen
provides HIV/AIDS services, integrated TB/HIV care, pre/post-natal care, chronic care,
mental health services and social welfare assistance to a primarily low-income population
residing in densely-populated peri-urban formal and informal settlements in northern
Johannesburg.
Pre-ART care at Witkoppen begins at the time of testing HIV positive using two
simultaneous rapid dried blood spot tests, with results available in about 20 minutes. Blood
for CD4 testing is drawn at the clinic on the same day a patient receives a positive HIV
result and is sent to an off-site National Health Laboratory Services (NHLS) facility.
Patients are scheduled to return for CD4 results 2–4 weeks after testing positive. At this
second visit, ART-eligible patients attend a first adherence counseling session and are
examined by a clinician. Blood is collected for additional baseline tests, and they are
scheduled to return 2–4 weeks later for a second adherence counseling session and ART
initiation. Patients initially ineligible for ART receive counseling about their CD4 result, are
examined by a clinician, and are scheduled to return for a follow-up CD4 test within six
months. Patients—both pre-ART and on-ART—who miss scheduled appointments are to be
phoned by clinic staff for rebooking, and if untraceable, to be referred for community
outreach tracing.
ART is initiated on-site by doctors and qualified nurses. Patients at Witkoppen are generally
treated according to the South African National Treatment Guidelines,22 with an important
exception. In 2010, Witkoppen began initiating all HIV-positive patients with a CD4 count
≤350 cells/mm3, a year before South Africa adopted this policy nationwide.23
Study design
We conducted an observational cohort study through retrospective clinical record review of
all non-pregnant adult individuals at Witkoppen testing HIV-positive for the first time
between 01 January–30 June 2010 (N=969). Starting with a roster of eligible patients
sourced from the clinic’s monthly HIV testing statistics, we excluded patients whose paper
files could not be located after three separate attempts using the clinic number provided and
were unlisted in TherapyEdge-HIV™, the electronic clinic HIV patient database (N=125),
suggesting an invalid clinic ID number or erroneous inclusion on the list of eligible patients.
We also excluded two patients who transferred facilities immediately after testing HIV-
positive. For the 842 patients included in the analysis, we reviewed clinic files after a
minimum of 12 months (median 16.5 months, IQR 14.8–18.1) from the time of testing HIV-
positive or at least 12 months post-initiation for those who were initially eligible for ART.
Data were collected using Microsoft Excel 2010 (Microsoft Corp., Redmond, WA).
Approval for this study was granted by the Human Research Ethics Committee of the
University of the Witwatersrand and the Institutional Review Board of the University of
North Carolina at Chapel Hill.
Definition of study variables
Retention was defined as remaining alive and in care at Witkoppen and was determined
using clinic visit dates. Attrition refers to both loss to follow-up (no clinic attendance ≥3
months after last scheduled visit) and death but does not include transfers. Patients who
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transfer are removed from the analysis at the start of the stage in which they transferred.
Missed visits among patients who returned to care and treatment interruptions do not
contribute to our definition of retention. We defined three stages of pre-ART care24 using
standardized definitions21 for retention in each stage as defined in Table 1. For pre-ART
stage 1, we report the proportion of patients who complete CD4 staging within three months
after testing HIV-positive. For pre-ART stage 2, we report the proportion of patients not
eligible for ART who received a second CD4 test within one year after the first CD4 staging.
Patients eligible for ART at the time of HIV diagnosis skip pre-ART stage 2 and move
directly to pre-ART stage 3, where we report the proportion of patients initiating ART
within three months after being determined ART-eligible. Eight patients (0.9%) reported
initiating ART at other facilities without transferring out and returned to Witkoppen, so the
date initiated elsewhere was used. We report post-ART retention at six and 12 months after
ART initiation. Retention within a stage is dependent on successfully completing the prior
stage. Cumulative retention analyses exclude patients who transferred during the stages
reported (n=59).
We defined initial CD4 count as the value at the time of testing HIV-positive. ART-
eligibility at the time of testing HIV-positive was confirmed during the file review and is
generally defined as a CD4 count ≤350 cells/mm3; however 23 patients with CD4 values
200–350 were considered ineligible for ART due to clinician non-compliance with the
clinic’s ART guidelines and three patients with CD4>350 were considered eligible at
clinician discretion. TB treatment was defined as initiating TB treatment within one year of
testing HIV-positive. For patients with an available South African ID number (33.9% of
patients lost to follow-up) mortality was confirmed using the National Population Register
of the South African Department of Home Affairs.25
Statistical analysis
Patient characteristics at the time of testing HIV-positive were summarized using counts and
proportions for categorical variables and medians and interquartile ranges (IQRs) for
continuous variables. We report retention at the three stages of pre-ART care and two ART
time points as counts and proportions with 95% confidence intervals (95%CI). We identified
predictors of any pre-ART or post-ART attrition by estimating adjusted risk ratios (aRR)
and 95%CI obtained by log-binomial regression analysis.
Results
Characteristics of the 842 eligible patients are summarized in Table 2. Overall, 55.1% were
female. Patients were a median (IQR) of 34 years (28–40) and had a median (IQR) initial
CD4 count of 211.5 (92–350) cells/mm3. Nearly half (41.5%) were born outside South
Africa, mostly in Zimbabwe (75.9% of foreign-born), and 72.6% tested HIV-positive on
their first visit to Witkoppen. Initial CD4 values were not available for 32 patients (3.8%)
due to the patient leaving prior to CD4 testing (n=25) or missing lab results (n=7) and never
returning for repeat testing. Of the remainder, 589 (72.7%) were ART-eligible when testing
HIV-positive. Nearly 11% of patients initiated TB treatment within a year of HIV testing.
Patient retention by stage
Retention through each of stage of pre- and post-ART care is shown in Figure 1, while
Figure 2 shows cumulative continuous retention through all stages of early HIV care.
Among patients newly-diagnosed with HIV, the greatest attrition occurred in pre-ART care,
with over 25% attrition at each of the three pre-ART stages (Figure 1) among those
remaining in care at the beginning of each stage. Overall retention in pre-ART stage 1 was
69.8% (95%CI 66.7%–72.9%) and included 32 subjects with no CD4 count, none of whom
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completed the stage. When limited to those with a CD4 count, retention was somewhat
higher for those ineligible for ART than those eligible when testing HIV positive (76.5% vs.
71.1%, respectively). The lowest proportion retained was in pre-ART stage 2 among those
ART-ineligible, with only 57.4% (95%CI 49.5–65.0%) of those who returned for their initial
CD4 results returning for a repeat CD4 test within one year. Median (IQR) CD4 value at
repeat testing among those previously ineligible for ART was 424 cells/mm3 (337–570) with
32.6% ART-eligible at their second CD4 staging. Retention after ART initiation was higher
than the pre-ART stages at 80.2% (95%CI 75.3–84.5%) between 0–6 months and 95.3%
(95%CI 91.7–97.6%) between 6–12 months.
The cumulative proportion of patients who were ART-eligible when testing HIV-positive
who remained in care through 12 months on ART was only 36.9% (95%CI 33.0–41.1%),
and among those ART-ineligible, 43.0% (95%CI 36.4–49.8%) were retained within one year
of initial CD4 staging (Figure 2). While attrition at each stage is substantial, overall attrition
steadies over time. Among those completing a stage (or retained for pre-ART stage 2), the
median (IQR) time to completing stage 1 (testing to completing staging) was 16 days (9–
28), stage 2 (completing staging until a repeat CD4 count) was 162 days (138–186), and
stage 3 (ART eligibility to ART initiation) was 23 days (12–36), suggesting most patients
who complete a stage do so within the defined time periods.
During the study period, 48 (5.7%, 95%CI 4.3–7.4%) patients died, however when we limit
this to the 38.8% (n=327) of the sample with a valid South Africa ID, mortality doubles to
11.9% (95%CI 8.7–15.8%). Initial CD4 results are available for 46 (95.8%) of the deceased
patients; of these, 87.0% were eligible for ART. Patients who died had a lower median
initial CD4 count (105 cells/mm3, IQR 49–169) than those who did not (225 cells/mm3, IQR
101–354), but did not differ from the overall cohort in terms of age, sex or TB treatment.
Among ART-eligible patients, 2.5% (95%CI 1.5–4.1%) of patients in pre-ART stage 1 and
3.9% (95%CI 2.4–6.2%) of patients in pre-ART stage 3 died. Following ART initiation,
2.4% (95%CI 1.1–4.8%) of patients died with less than six months on treatment and 1.0%
(95%CI 0.2–3.1%) with more than six months on ART. Among patients who were ART-
ineligible, none died during pre-ART stage 1 and 2.7% (95%CI 1.1–5.6%) of patients in pre-
ART stage 2 died. Overall, 77.5% of ART-eligible patients who died did not initiate ART.
Predictors of pre-ART and post-ART attrition
Younger age (18–29 years) was associated with increased attrition in the pre-ART stages
(aRR 1.56, 95%CI 1.21, 2.00), and possibly after ART initiation (aRR 1.27, 95%CI 0.76,
2.13), compared to age 30–39 (Table 3). An initial CD4 <50 cells/mm3 predicted increased
attrition before (aRR 1.51, 95%CI 1.08, 2.12) and after ART initiation (aRR 2.30, 95%CI
1.15, 4.63), compared to an initial CD4 200–350 cells/mm3. Male sex was associated with
increased likelihood of attrition before ART (aRR 1.47, 95%CI 1.16, 1.87), but not after
ART initiation (aRR 0.76, 95%CI 0.45, 1.28). Patients born outside of South Africa tended
to fail to complete 12 months on ART (aRR 1.48, 95%CI 0.92, 2.40) compared to their
South African counterparts. TB treatment was strongly associated with decreased attrition in
the pre-ART stage (aRR 0.04, 95%CI 0.01, 0.27), but not following ART initiation (aRR
1.42, 95%CI 0.79, 2.53).
Discussion
Retention in HIV care from the time of testing positive through lifelong ART treatment is
critical for getting patients onto treatment promptly and for preventing morbidity and
mortality associated with disease progression. This study, one of the first to follow a
consistent cohort of newly-diagnosed HIV-positive patients over a year through the various
stages of pre-ART and early ART care, allowed us to summarize attrition throughout early
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HIV care. Our findings paint a stark picture—the proportion of patients ART-eligible when
testing positive retained continuously in care through one year on ART was under 40%. This
suggests that the majority of patients in our study continued to be at high risk of HIV-
associated death and opportunistic infections despite knowing their HIV-positive status.
This finding is consistent with a previous review of sub-Saharan African studies that
estimated overall retention in pre-ART care to be 33%.24 One critical problem however with
summarizing previous studies’ results is a lack of consistent definitions of retention and time
periods over which retention was measured. Thus while many studies have previously
documented high pre-ART14–18 and on-ART attrition7–11 at specific stages in care, our
finding of substantial patient loss throughout the stages of early HIV care is one of the only
studies to document this in a single cohort of ART-eligible and ineligible patients using
standardized definitions.21 Studies that only investigate retention in disjointed cohorts are
also unable to comment on the timing of attrition. We found that the pre-ART periods are a
time of considerable loss, with over one-quarter of patients still in care lost at each stage.
Our results also document the challenge of retention among patients ineligible for ART at
the time of testing positive for HIV. Given that South Africa guidelines call for repeat CD4
testing every six months,22 the pre-ART stage 2 definition used gives patients ample time to
return. Despite this, we found only 57.4% (95%CI 49.5–65.0%) of ART-ineligible
individuals completed a repeat CD4 count within one year. This is true despite the fact that
pre-ART services were available at the same clinic where the patient completed HIV testing
and CD4 staging and did not require visiting a separate location. While low, our retention
results are higher than other recent studies from South Africa which have shown retention
for patients not yet eligible for ART to be between 36.0% and 46.3%,16,17 and consistent
with a meta-analysis result of 54.2% among ART-ineligible patients in sub-Saharan
Africa.26
The majority of patients in our study were ART-eligible when testing positive for HIV under
the site’s threshold of a CD4 count ≤350 cells/mm3. Among these eligible patients, for
whom moving from HIV diagnosis to CD4 staging to ART initiation can be completed
within two to eight weeks, attrition was greatest in pre-ART care. In just these few first
weeks, patient attrition was 28.9% (95%CI 25.3–32.6%) from testing to CD4 staging and
26.5% (95%CI 22.4–31.0%) from ART eligibility to ART initiation. For those who initiated
treatment, attrition 0–12 months after ART initiation remained high overall at 25.0%
(95%CI 20.1–30.4%), but most attrition occurred during 0–6 months on ART (19.8%,
95%CI 15.5–24.7%) and stabilized between 6–12 months on ART (4.7%, 95%CI 2.4–
8.3%). This finding suggests that if patients have the motivation and support to complete the
early milestones of CD4 staging and ART initiation, they are likely to remain in care. Given
the substantial proportion (28.9%) of ART-eligible patients who did not return for their
second clinic visit to receive CD4 results, the challenge is to retain patients within the very
first weeks of HIV care: from diagnosis through CD4 staging and ART initiation.
Recognition of this challenge has encouraged new efforts to retain these patients, including
offering point-of-care CD4 technology and same-day ART initiation.27–29
We identified several important predictors of patient attrition within the first year of HIV
care (Table 3). Differing directions of estimates for predictors of pre-ART or post-ART
attrition indicate that there may be different drivers of retention within each group at these
unique stages that require specific, targeted interventions. For example, males had greater
attrition in the pre-ART stages, but no gender difference was observed post-ART. Overall,
our findings are consistent with other studies noting poorer retention among
males9,11,16,18,19 and younger patients9,11,16 and highlight the need for interventions
targeted to these specific groups, such as improved male involvement approaches, youth-
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friendly services, mobile technology and others. Patients on TB treatment had much less
likelihood of attrition during pre-ART stages, which differs from the results of an ART-
eligible Durban cohort where newly-diagnosed TB patients experienced 76% greater
attrition than TB-free patients.30 Our finding likely is due to regular follow-up at the clinic
during TB treatment and active tracing of those who default TB treatment. After ART
initiation, patients in our study were as likely, or possibly more likely, to drop out of care as
those not on TB treatment, highlighting the importance of communicating the need for
regular ART care beyond the TB treatment period. Being born outside of South Africa was
associated with a nearly 50% increased likelihood of attrition following ART initiation,
similar to Bygrave, et al,31 but in contrast to better retention in care among self-identified
foreigners in South Africa found by McKarthy, et al. 32 Witkoppen has a very high
proportion of patients born outside of South Africa, which is becoming increasingly
common in Johannesburg public-sector clinics, if not throughout the country.28,33 In
addition to migration among immigrant patients, clinics should evaluate the potential for
short- or long-term migration away from the clinic among immigrant and South African
patients, and facilitate links to care and provide sufficient drug supply.
Mortality in our study was low at 5.7%. Even though we used the South Africa Department
of Home Affairs National Population Register to verify deaths, which has been shown to be
80% complete for adults with valid ID numbers,34 this estimate of overall mortality likely is
underestimated as nearly half of our cohort was not South African and when we limited our
mortality estimate to only those with a valid South African ID, mortality doubled. It is
difficult to compare our mortality to findings of other studies since most focus only on either
pre-ART or post-ART mortality. Among patients who died who were eligible for ART, we
found that the majority of deaths occurred prior to ART initiation, further emphasizing the
importance of linkage to care during the critical pre-ART period and the need to fast-track
patients with severe immunosuppression.
Our results should be interpreted in light of their limitations. First, the generalizability of our
results may be limited given that our data represent only one facility. Retention may have
been higher than in most settings given the integration of HIV testing and care on-site.
Previous studies suggest that moving from facility to facility for CD4 testing, ART
initiation, etc., may encourage attrition.20,35 Second, retention may be underestimated as
some patients considered lost in our analysis may have continued care and initiated
treatment elsewhere. We only know of the intention to continue care elsewhere among
patients who requested a transfer, a common limitation of studies investigating patient
retention. Third, we defined attrition based on visit dates, which does not consider missed
visits or treatment interruptions, which may overestimate the true amount of patient
engagement in care. Finally, due to high patient drop-out throughout the study period, our
sample size was reduced by the post-ART stages, limiting the precision of our regression
analysis estimates for this period. Strengths of our study include a comprehensive dataset
that allows for retention estimates from the point of testing HIV-positive through ART
retention with few missing data. The study was conducted under routine clinical conditions
and represents patient retention within a real-world scenario at one clinic.
Our findings help to explicate the problem of attrition from HIV programs throughout the
continuum of early HIV care. In our study, patient attrition was highest during the pre-ART
period, but our findings suggest that once patients initiate ART, they are more likely to be
retained. These findings support the need for retention interventions that target patient loss
from the very first visit when a patient learns their HIV-positive diagnosis.
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Figure 1. Study profile of completion of key stages of early HIV care among 842 newly diagnosed
HIV-positive patients at an HIV treatment program in South Africa
Stage completion is dependent on completing the prior stage in the time period specified.
Patients eligible for ART per CD4 value at the time of HIV testing skip Pre-ART Stage 2
and move directly to Pre-ART Stage 3.
*12 month ART retention data not available by the end of data collection.
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Figure 2. Cumulative patient retention from HIV diagnosis through one year on ART for 544
HIV-positive patients eligible for ART, and one year after initial CD4 staging for 207 HIV-
positive patients ineligible for ART
Error bars indicate 95% confidence intervals on the proportions.
Stage completion is dependent on completing the prior stage in the time period specified.
*Patients eligible for ART at the time of HIV testing skip pre-ART stage 2 and proceed
directly to pre-ART stage 3.
Patients who transferred during the stages shown were excluded from this analysis (n=59).
Clouse et al. Page 12




















































































































































































































































































































































































































































































































































































































Clouse et al. Page 14
Table 2
Characteristics of the study participants (N=842).
Sex, n (%)
 Female 464 (55.1)
 Male 378 (44.9)
Age at HIV testing, median (IQR) 34 (28–40)
Age at HIV testing, n (%)
 18–29 years 254 (30.2)
 30–39 years 352 (41.8)
 40 years and older 236 (28.0)
First CD4 value (cells/mm3), median (IQR) 211.5 (92–350)
First CD4 value, n (%)
 <50 cells/mm3 102 (12.1)
 50–199 cells/mm3 282 (33.5)
 200–350 cells/mm3 225 (26.7)
 >350 cells/mm3 201 (23.9)
 Missing 32 (3.8)
Nationality, n (%)
 Born in South Africa 468 (55.6)
 Born outside of South Africa 349 (41.5)
 Missing 25 (3.0)
Employment status, n (%)
 Employed 435 (51.7)
 Not employed 386 (45.8)
 Missing 21 (2.5)
HIV-positive at first clinic visit, n (%)
 Yes 611 (72.6)
 No 229 (27.2)
 Missing 2 (0.2)
TB treatment*, n (%)




Initiated TB treatment within one year from the time of testing HIV-positive.
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